Compare Edwards Lifesciences Corporation Common Stock (EW) vs Jumia Technologies AG - ADR (JMIA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Edwards Lifesciences Corporation Common Stock vs Jumia Technologies AG - ADR — how do they compare? Edwards Lifesciences Corporation Common Stock trades at $84.25 (market cap $49.44B), while Jumia Technologies AG - ADR trades at $6.53 (market cap $900.64M). The key difference: Edwards Lifesciences Corporation Common Stock is far larger — about 54.9× Jumia Technologies AG - ADR's market cap, and Edwards Lifesciences Corporation Common Stock is trading nearer its 52-week high, Jumia Technologies AG - ADR nearer its low. Which is the better fit depends on your goals.
| EW | JMIA | |
|---|---|---|
Market Cap | $49.44B | $900.64M |
Volume | 3,508,027 | 625,675 |
Sector | Health | Consumer Cyclical |
52-Week High | $95.18 | $14.60 |
52-Week Low | $72.65 | $5.69 |
Enterprise Value | $45.90B | $866.28M |
Typical Hold Time | — | 28 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
JMIA trades at $6.48, down 4.71% today, with bearish technical signals from moving averages. The company shows improving fundamentals with revenue growth from $167M in 2024 to $189M in 2025 and narrowing losses, though it remains unprofitable with a -27.54% net margin. Recent news highlights a $50M capital raise and progress toward EBITDA breakeven by year-end 2026.
Analyst consensus is bullish with a $12 price target (71% buy ratings), but risks include persistent losses, high P/B ratio of 1,014, and negative cash flow from operations. The path to profitability and African market execution are critical for upside realization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Edwards Lifesciences Corporation Common Stock
Edwards Lifesciences develops medical technologies for structural heart disease. Its products include transcatheter aortic-valve replacement, mitral and tricuspid therapies, and surgical structural-heart technologies.
Read more on EW →About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →
